Lung Cancer Therapeutics Market, 2012 to 2023
Global Lung Cancer Therapeutics Market
Lung cancer or lung carcinoma is the disease characterized by the abnormal proliferation of tumour cells in the lung tissues. Lung cancer is classified into 3 types namely lung carcinoid tumour, small cell lung cancer, and non-small cell lung cell cancer. Common symptoms associated with the lung cancer include a cough, weight loss, shortness of breath, and chest pains. Smoking and prolonged use of tobacco are the common risk factors for the lung cancer. Lung cancer can be diagnosed by the biopsy performed by using CT-guidance or bronchoscopy. Lung cancer can be treated by radiotherapy, chemotherapy, and surgery.
Increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of lung cancer therapeutics market. Moreover, innovation of newer radiotherapies, a launch of low priced generic drugs, and rise in prevalence of non-small cell lung cancer are expected to propel the lung cancer therapeutics market over the forecast period. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the growth of lung cancer therapeutics market.
Lung cancer therapeutics market segmented based on the treatment type, disease type, and end user
Based on the drug type, lung cancer therapeutics market segmented into the following:
Chemotherapy
Taxol
Navelbine
Alimta
Cisplatin
Camptosar
Others
Targeted therapy
Gilotrif
Tarceva
Avastin
Iressa
Others
Based on the disease type, lung cancer therapeutics market segmented into the following:
Small cell lung cancer
Non-small cell lung cancer
Large carcinoid tumour
Based on the end user, lung cancer therapeutics market segmented into the following:
Hospitals
Oncology Clinics
Ambulatory surgical centres
Global lung cancer therapeutics market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccines for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the lung cancer therapeutics market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in lung cancer therapeutics market. For instance, in November 2015, Eli Lilly and Co. and Merck & Co., Inc. collaborated to evaluate the efficacy and safety of a combination of the Alimta and Keytruda under phase III trials for the treatment of non-small cell lung cancer. Moreover, in January 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer. Similarly, In September 2014, Asterias Biotherapeutics collaborated with Cancer Research UK for the development of a vaccine for the treatment of non-small cell lung cancer.
Geographically, Lung cancer therapeutics market is segmented into the Europe, Latin America, Asia Pacific, Middle East and Africa, and North America. North America lung cancer therapeutics market is growing due to increase in the prevalence of lung cancer majorly in U.S. (according to CDC 2014, about 215,951 people diagnosed with lung cancer and 155,526 people died of the lung cancer). In addition, increase the funding for the R&D activities, and early diagnosis of the disease is expected to propel the lung cancer therapeutics market in North America. In Europe region, rise in the prevalence of lung cancer majorly in Hungary, Serbia, U.K and other Europe countries (according to Cancer Research UK, about 46,403 new lung cancer in the UK and 35,895 people died of the disease), rise in the government funding for lung cancer R&D activities, and advanced healthcare infrastructure are boosting the lung cancer therapeutics market. Asia Pacific region is exhibiting significant growth in lung cancer therapeutics market owing to rapid industrialization and availability of low-cost generic products in the region.
Some of the players in lung cancer therapeutics market are Eli Lilly and Company (U.S.), GlaxoSmithKline Plc (U.K.), AstraZeneca (U.S.), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co. Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Novartis AG (Switzerland), Takeda Pharmaceuticals Co. Ltd. (Japan), Abbvie, Inc. (U.S.), VisionGate, Inc. (U.S.), and Asterias Biotherapeutics (Biotime) (U.S.) to name a few.
In April 2017, Takeda Pharmaceutical received an approval from FDA for Alunbrig (brigatinib) used in the treatment of ALK+ non-small cell lung cancer
In April 2017, AstraZeneca received approval from European Commission for the marketing authorization of Tagrisso used in the treatment of non-small cell lung cancer
Lung cancer or lung carcinoma is the disease characterized by the abnormal proliferation of tumour cells in the lung tissues. Lung cancer is classified into 3 types namely lung carcinoid tumour, small cell lung cancer, and non-small cell lung cell cancer. Common symptoms associated with the lung cancer include a cough, weight loss, shortness of breath, and chest pains. Smoking and prolonged use of tobacco are the common risk factors for the lung cancer. Lung cancer can be diagnosed by the biopsy performed by using CT-guidance or bronchoscopy. Lung cancer can be treated by radiotherapy, chemotherapy, and surgery.
Increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of lung cancer therapeutics market. Moreover, innovation of newer radiotherapies, a launch of low priced generic drugs, and rise in prevalence of non-small cell lung cancer are expected to propel the lung cancer therapeutics market over the forecast period. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the growth of lung cancer therapeutics market.
Lung cancer therapeutics market segmented based on the treatment type, disease type, and end user
Based on the drug type, lung cancer therapeutics market segmented into the following:
Chemotherapy
Taxol
Navelbine
Alimta
Cisplatin
Camptosar
Others
Targeted therapy
Gilotrif
Tarceva
Avastin
Iressa
Others
Based on the disease type, lung cancer therapeutics market segmented into the following:
Small cell lung cancer
Non-small cell lung cancer
Large carcinoid tumour
Based on the end user, lung cancer therapeutics market segmented into the following:
Hospitals
Oncology Clinics
Ambulatory surgical centres
Global lung cancer therapeutics market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccines for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the lung cancer therapeutics market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in lung cancer therapeutics market. For instance, in November 2015, Eli Lilly and Co. and Merck & Co., Inc. collaborated to evaluate the efficacy and safety of a combination of the Alimta and Keytruda under phase III trials for the treatment of non-small cell lung cancer. Moreover, in January 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer. Similarly, In September 2014, Asterias Biotherapeutics collaborated with Cancer Research UK for the development of a vaccine for the treatment of non-small cell lung cancer.
Geographically, Lung cancer therapeutics market is segmented into the Europe, Latin America, Asia Pacific, Middle East and Africa, and North America. North America lung cancer therapeutics market is growing due to increase in the prevalence of lung cancer majorly in U.S. (according to CDC 2014, about 215,951 people diagnosed with lung cancer and 155,526 people died of the lung cancer). In addition, increase the funding for the R&D activities, and early diagnosis of the disease is expected to propel the lung cancer therapeutics market in North America. In Europe region, rise in the prevalence of lung cancer majorly in Hungary, Serbia, U.K and other Europe countries (according to Cancer Research UK, about 46,403 new lung cancer in the UK and 35,895 people died of the disease), rise in the government funding for lung cancer R&D activities, and advanced healthcare infrastructure are boosting the lung cancer therapeutics market. Asia Pacific region is exhibiting significant growth in lung cancer therapeutics market owing to rapid industrialization and availability of low-cost generic products in the region.
Some of the players in lung cancer therapeutics market are Eli Lilly and Company (U.S.), GlaxoSmithKline Plc (U.K.), AstraZeneca (U.S.), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co. Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Novartis AG (Switzerland), Takeda Pharmaceuticals Co. Ltd. (Japan), Abbvie, Inc. (U.S.), VisionGate, Inc. (U.S.), and Asterias Biotherapeutics (Biotime) (U.S.) to name a few.
In April 2017, Takeda Pharmaceutical received an approval from FDA for Alunbrig (brigatinib) used in the treatment of ALK+ non-small cell lung cancer
In April 2017, AstraZeneca received approval from European Commission for the marketing authorization of Tagrisso used in the treatment of non-small cell lung cancer
1. EXECUTIVE SUMMARY
2. GLOBAL LUNG CANCER THERAPEUTICS MARKET INTRODUCTION
2.1. Global Lung Cancer Therapeutics Market – Taxonomy
2.2. Global Lung Cancer Therapeutics Market –Definitions
2.2.1. Drug class
2.2.2. Distribution Channel
3. GLOBAL LUNG CANCER THERAPEUTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Lung Cancer Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Lung Cancer Therapeutics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Lung Cancer Therapeutics Market – Pipeline Analysis
4. GLOBAL LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Chemotherapy
5.1.1.1. Taxol
5.1.1.2. Navelbine
5.1.1.3. Alimta
5.1.1.4. Cisplatin
5.1.1.5. Camptosar
5.1.1.6. Others
5.1.2. Targeted therapy
5.1.2.1. Gilotrif
5.1.2.2. Tarceva
5.1.2.3. Avastin
5.1.2.4. Iressa
5.1.2.5. Others
5.1.3. Market Opportunity Analysis
6. GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Small Cell Lung Cancer
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Non-Small Cell Lung Cancer
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Large Carcinoid Tumor
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospitals
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Oncology Clinics
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Ambulatory Surgical Centers
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Diseases Type, End User, and Region, 2017 – 2023
9. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.2. Chemotherapy
9.1.2.1. Taxol
9.1.2.2. Navelbine
9.1.2.3. Alimta
9.1.2.4. Cisplatin
9.1.2.5. Camptosar
9.1.2.6. Others
9.1.3. Targeted therapy
9.1.3.1. Gilotrif
9.1.3.2. Tarceva
9.1.3.3. Avastin
9.1.3.4. Iressa
9.1.3.5. Others
9.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. Small cell lung cancer
9.1.4.2. Non-small cell lung cancer
9.1.4.3. Large carcinoid tumor
9.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.5.1. Hospitals
9.1.5.2. Oncology Clinics
9.1.5.3. Ambulatory Surgical Centers
9.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.6.1. U.S.
9.1.6.2. Canada
9.1.7. North America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Disease Type, End User and Country, 2017 – 2023
9.1.8. North America Lung Cancer Therapeutics Market Dynamics – Trends
10. EUROPE LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Chemotherapy
10.1.2.1. Taxol
10.1.2.2. Navelbine
10.1.2.3. Alimta
10.1.2.4. Cisplatin
10.1.2.5. Camptosar
10.1.2.6. Others
10.1.3. Targeted therapy
10.1.3.1. Gilotrif
10.1.3.2. Tarceva
10.1.3.3. Avastin
10.1.3.4. Iressa
10.1.3.5. Others
10.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Small cell lung cancer
10.1.4.2. Non-small cell lung cancer
10.1.4.3. Large carcinoid tumor
10.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. Hospitals
10.1.5.2. Oncology Clinics
10.1.5.3. Ambulatory Surgical Centers
10.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.6.1. Germany
10.1.6.2. UK
10.1.6.3. France
10.1.6.4. Spain
10.1.6.5. Italy
10.1.6.6. Russia
10.1.6.7. Poland
10.1.6.8. Rest of Europe
10.1.7. Europe Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
10.1.8. Europe Lung Cancer Therapeutics Market Dynamics – Trends
11. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Chemotherapy
11.1.2.1. Taxol
11.1.2.2. Navelbine
11.1.2.3. Alimta
11.1.2.4. Cisplatin
11.1.2.5. Camptosar
11.1.2.6. Others
11.1.3. Targeted therapy
11.1.3.1. Gilotrif
11.1.3.2. Tarceva
11.1.3.3. Avastin
11.1.3.4. Iressa
11.1.3.5. Others
11.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Small cell lung cancer
11.1.4.2. Non-small cell lung cancer
11.1.4.3. Large carcinoid tumor
11.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5.1. Hospitals
11.1.5.2. Oncology Clinics
11.1.5.3. Ambulatory Surgical Centers
11.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.6.1. Japan
11.1.6.2. China
11.1.6.3. India
11.1.6.4. ASEAN
11.1.6.5. Australia & New Zealand
11.1.6.6. Rest of Asia-Pacific
11.1.7. Asia-Pacific Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
11.1.8. Europe Lung Cancer Therapeutics Market Dynamics – Trends
12. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Chemotherapy
12.1.2.1. Taxol
12.1.2.2. Navelbine
12.1.2.3. Alimta
12.1.2.4. Cisplatin
12.1.2.5. Camptosar
12.1.2.6. Others
12.1.3. Targeted therapy
12.1.3.1. Gilotrif
12.1.3.2. Tarceva
12.1.3.3. Avastin
12.1.3.4. Iressa
12.1.3.5. Others
12.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Small cell lung cancer
12.1.4.2. Non-small cell lung cancer
12.1.4.3. Large carcinoid tumor
12.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.5.1. Hospitals
12.1.5.2. Oncology Clinics
12.1.5.3. Ambulatory Surgical Centers
12.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.6.1. Brazil
12.1.6.2. Mexico
12.1.6.3. Argentina
12.1.6.4. Venezuela
12.1.6.5. Rest of Latin America
12.1.7. Latin America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
12.1.8. Latin America Lung Cancer Therapeutics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2. Chemotherapy
13.1.2.1. Taxol
13.1.2.2. Navelbine
13.1.2.3. Alimta
13.1.2.4. Cisplatin
13.1.2.5. Camptosar
13.1.2.6. Others
13.1.3. Targeted therapy
13.1.3.1. Gilotrif
13.1.3.2. Tarceva
13.1.3.3. Avastin
13.1.3.4. Iressa
13.1.3.5. Others
13.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Small cell lung cancer
13.1.4.2. Non-small cell lung cancer
13.1.4.3. Large carcinoid tumor
13.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5.1. Hospitals
13.1.5.2. Oncology Clinics
13.1.5.3. Ambulatory Surgical Centers
13.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.6.1. Gulf Cooperation Council (GCC) Countries
13.1.6.2. Israel
13.1.6.3. South Africa
13.1.6.4. Rest of MEA
13.1.7. MEA Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
13.1.8. MEA Lung Cancer Therapeutics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AstraZeneca Plc. (UK)
14.2.2. Merck & Co., Inc. (U.S.)
14.2.3. Pfizer, Inc. (U.S.)
14.2.4. Novartis AG (Switzerland)
14.2.5. Boehringer Ingelheim International GmbH (Germany)
14.2.6. Takeda Pharmaceutical Company Limited (Japan)
14.2.7. Abbvie, Inc (U.S.)
14.2.8. Vision Gate, Inc (U.S)
14.2.9. Asterias Biotherapeutics (Biotime) (U.S.)
14.2.10. GlaxoSmithKline Plc (U.K.)
14.2.11. F. Hoffmann La Roche (Switzerland)
14.2.12. Eli Lilly and Company (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONY
2. GLOBAL LUNG CANCER THERAPEUTICS MARKET INTRODUCTION
2.1. Global Lung Cancer Therapeutics Market – Taxonomy
2.2. Global Lung Cancer Therapeutics Market –Definitions
2.2.1. Drug class
2.2.2. Distribution Channel
3. GLOBAL LUNG CANCER THERAPEUTICS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Lung Cancer Therapeutics Market Dynamics – Factors Impact Analysis
3.6. Global Lung Cancer Therapeutics Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Lung Cancer Therapeutics Market – Pipeline Analysis
4. GLOBAL LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Chemotherapy
5.1.1.1. Taxol
5.1.1.2. Navelbine
5.1.1.3. Alimta
5.1.1.4. Cisplatin
5.1.1.5. Camptosar
5.1.1.6. Others
5.1.2. Targeted therapy
5.1.2.1. Gilotrif
5.1.2.2. Tarceva
5.1.2.3. Avastin
5.1.2.4. Iressa
5.1.2.5. Others
5.1.3. Market Opportunity Analysis
6. GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Small Cell Lung Cancer
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Non-Small Cell Lung Cancer
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Large Carcinoid Tumor
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospitals
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Oncology Clinics
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Ambulatory Surgical Centers
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL LUNG CANCER THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Diseases Type, End User, and Region, 2017 – 2023
9. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.2. Chemotherapy
9.1.2.1. Taxol
9.1.2.2. Navelbine
9.1.2.3. Alimta
9.1.2.4. Cisplatin
9.1.2.5. Camptosar
9.1.2.6. Others
9.1.3. Targeted therapy
9.1.3.1. Gilotrif
9.1.3.2. Tarceva
9.1.3.3. Avastin
9.1.3.4. Iressa
9.1.3.5. Others
9.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. Small cell lung cancer
9.1.4.2. Non-small cell lung cancer
9.1.4.3. Large carcinoid tumor
9.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.5.1. Hospitals
9.1.5.2. Oncology Clinics
9.1.5.3. Ambulatory Surgical Centers
9.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.6.1. U.S.
9.1.6.2. Canada
9.1.7. North America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Disease Type, End User and Country, 2017 – 2023
9.1.8. North America Lung Cancer Therapeutics Market Dynamics – Trends
10. EUROPE LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.2. Chemotherapy
10.1.2.1. Taxol
10.1.2.2. Navelbine
10.1.2.3. Alimta
10.1.2.4. Cisplatin
10.1.2.5. Camptosar
10.1.2.6. Others
10.1.3. Targeted therapy
10.1.3.1. Gilotrif
10.1.3.2. Tarceva
10.1.3.3. Avastin
10.1.3.4. Iressa
10.1.3.5. Others
10.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Small cell lung cancer
10.1.4.2. Non-small cell lung cancer
10.1.4.3. Large carcinoid tumor
10.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. Hospitals
10.1.5.2. Oncology Clinics
10.1.5.3. Ambulatory Surgical Centers
10.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.6.1. Germany
10.1.6.2. UK
10.1.6.3. France
10.1.6.4. Spain
10.1.6.5. Italy
10.1.6.6. Russia
10.1.6.7. Poland
10.1.6.8. Rest of Europe
10.1.7. Europe Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
10.1.8. Europe Lung Cancer Therapeutics Market Dynamics – Trends
11. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.2. Chemotherapy
11.1.2.1. Taxol
11.1.2.2. Navelbine
11.1.2.3. Alimta
11.1.2.4. Cisplatin
11.1.2.5. Camptosar
11.1.2.6. Others
11.1.3. Targeted therapy
11.1.3.1. Gilotrif
11.1.3.2. Tarceva
11.1.3.3. Avastin
11.1.3.4. Iressa
11.1.3.5. Others
11.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Small cell lung cancer
11.1.4.2. Non-small cell lung cancer
11.1.4.3. Large carcinoid tumor
11.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5.1. Hospitals
11.1.5.2. Oncology Clinics
11.1.5.3. Ambulatory Surgical Centers
11.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.6.1. Japan
11.1.6.2. China
11.1.6.3. India
11.1.6.4. ASEAN
11.1.6.5. Australia & New Zealand
11.1.6.6. Rest of Asia-Pacific
11.1.7. Asia-Pacific Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
11.1.8. Europe Lung Cancer Therapeutics Market Dynamics – Trends
12. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.2. Chemotherapy
12.1.2.1. Taxol
12.1.2.2. Navelbine
12.1.2.3. Alimta
12.1.2.4. Cisplatin
12.1.2.5. Camptosar
12.1.2.6. Others
12.1.3. Targeted therapy
12.1.3.1. Gilotrif
12.1.3.2. Tarceva
12.1.3.3. Avastin
12.1.3.4. Iressa
12.1.3.5. Others
12.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Small cell lung cancer
12.1.4.2. Non-small cell lung cancer
12.1.4.3. Large carcinoid tumor
12.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.5.1. Hospitals
12.1.5.2. Oncology Clinics
12.1.5.3. Ambulatory Surgical Centers
12.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.6.1. Brazil
12.1.6.2. Mexico
12.1.6.3. Argentina
12.1.6.4. Venezuela
12.1.6.5. Rest of Latin America
12.1.7. Latin America Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
12.1.8. Latin America Lung Cancer Therapeutics Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.2. Chemotherapy
13.1.2.1. Taxol
13.1.2.2. Navelbine
13.1.2.3. Alimta
13.1.2.4. Cisplatin
13.1.2.5. Camptosar
13.1.2.6. Others
13.1.3. Targeted therapy
13.1.3.1. Gilotrif
13.1.3.2. Tarceva
13.1.3.3. Avastin
13.1.3.4. Iressa
13.1.3.5. Others
13.1.4. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Small cell lung cancer
13.1.4.2. Non-small cell lung cancer
13.1.4.3. Large carcinoid tumor
13.1.5. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5.1. Hospitals
13.1.5.2. Oncology Clinics
13.1.5.3. Ambulatory Surgical Centers
13.1.6. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.6.1. Gulf Cooperation Council (GCC) Countries
13.1.6.2. Israel
13.1.6.3. South Africa
13.1.6.4. Rest of MEA
13.1.7. MEA Lung Cancer Therapeutics Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
13.1.8. MEA Lung Cancer Therapeutics Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AstraZeneca Plc. (UK)
14.2.2. Merck & Co., Inc. (U.S.)
14.2.3. Pfizer, Inc. (U.S.)
14.2.4. Novartis AG (Switzerland)
14.2.5. Boehringer Ingelheim International GmbH (Germany)
14.2.6. Takeda Pharmaceutical Company Limited (Japan)
14.2.7. Abbvie, Inc (U.S.)
14.2.8. Vision Gate, Inc (U.S)
14.2.9. Asterias Biotherapeutics (Biotime) (U.S.)
14.2.10. GlaxoSmithKline Plc (U.K.)
14.2.11. F. Hoffmann La Roche (Switzerland)
14.2.12. Eli Lilly and Company (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONY
